Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 18 Jul 2016 Planned End Date changed from 1 Nov 2017 to 1 Jan 2018.
- 18 Jul 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Jan 2018.
- 01 Feb 2015 Planned number of patients changed from 1500 to 111 as reported by ClinicalTrials.gov.